A study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a class of precision cancer drugs called PARP inhibitors.

A study led by NYU Langone Health researchers sheds light on how the major cancer gene BRCA2 determines which cancer cells ...

Mutations in BRCA2—a gene known to repair damaged DNA and suppress tumor formation—can predict an individual's predisposition ...

Inherited mutations in the gene BRCA2 significantly increase the risk of carriers to breast and ovarian cancers.  BRCA2, a crucial player in the body& | Cancer ...

On one hand, it represses PARP1 catalytic activity and associated DNA damage repair. On the other hand, it also protects cells from overconsuming nicotinamide adenine dinucleotide—a coenzyme ...

A new study led by scientists at NYU Langone Health sheds light on how the major cancer gene BRCA2 determines which cancer cells can be killed by a ...

Powered Drug DiscoveryVANCOUVER, British Columbia, March 25, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) ...

Santa Cruz Biotechnology, Inc.’s PARP1 CRISPR plasmids are optimized for research use that can lead to disease treatment advances. For example, the PARP1 homology-directed repair (HDR) plasmid ...

The PARP protein family comprises 17 members, but PARP1 and PARP2 are the main proteins involved in DNA repair. Both proteins regulate the DDR network, but PARP1 also regulates transcription and ...

So, as BRCA-deficient cells had previously been shown to be highly sensitive to the effects of inhibiting PARP1, Rottenberg and colleagues investigated the effects of the PARP1 inhibitor AZD2281 ...

Merck gets exclusive rights to Hengrui’s PARP1 drug HRS-1167 outside China under the terms of the agreement, and also picks up an option for an ex-China license to SHR-A1904, an ADC directed at ...